Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 8/20 | 0.64 |
| ▸ | TP53 | P04637 | 6/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7881270 | 0.87 | L3MBTL1 (0.59) | L3MBTL1MAPTLMNATP53THRB | |
| SCHEMBL28265749 | 0.86 | THRB (0.57) | L3MBTL1MAPTLMNATP53THRB | |
| SCHEMBL11529770 | 0.84 | MAPT (0.67) | L3MBTL1MAPTLMNATP53THRB | |
| SCHEMBL18067891 | 0.84 | L3MBTL1 (0.72) | L3MBTL1MAPTLMNATP53THRB | |
| SCHEMBL5426590 | 0.84 | L3MBTL1 (1.00) | L3MBTL1MAPTLMNATP53KDM4E | |
| SCHEMBL20559065 | 0.83 | L3MBTL1 (0.70) | L3MBTL1MAPTLMNATP53MEN1 | |
| SCHEMBL3061254 | 0.83 | L3MBTL1 (0.70) | L3MBTL1MAPTLMNATP53THRB | |
| SCHEMBL4919697 | 0.83 | L3MBTL1 (0.70) | L3MBTL1MAPTRXFP1MEN1KMT2A | |
| SCHEMBL1096760 | 0.83 | L3MBTL1 (0.70) | L3MBTL1MAPTLMNATP53KDM4E | |
| SCHEMBL30547707 | 0.81 | KDM4E (0.68) | L3MBTL1MAPTLMNATP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2023129933-A2 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2017061710-A1 | NOVEL INDOLE-2-CARBOXYLATE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2017-04-13 | — | — | WO | disclosed |
| CN-1067988-C | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 2001-07-04 | — | — | CN | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| CN-1051301-C | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 2000-04-12 | — | — | CN | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| CN-1136038-A | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICS K K (JP) | 1996-11-20 | — | — | CN | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| CN-1106800-A | Indoloylguanidine derivatives | SUMITOMO PHARMA (JP) | 1995-08-16 | — | — | CN | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, METTL16, TPMT | L3MBTL1 11/4885MAPT 817/4885LMNA 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.